Elutia agrees to sell SimpliDerm business to Cellution Biologics for up to $11 million

Elutia Inc Class A

Elutia Inc Class A

ELUT

0.00
  • Elutia signed a definitive deal to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to USD 11 million.
  • Terms include USD 8 million cash at closing, with up to USD 3 million tied to technology transfer and commercial milestones over 18 months.
  • Closing is expected in the second half of 2026, subject to customary conditions.
  • Divestiture shifts focus to NXT-41x, targeting a 2027 commercial launch in U.S. plastic and reconstructive surgery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elutia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607161605PRIMZONEFULLFEED9763644) on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.